Research is being conducted on the use of trifluridine-tipiracil and bevacizumab in treating refractory metastatic colorectal cancer. The combination of these treatments is being studied in various phases of clinical trials, including phase II and phase III studies. The treatment appears to provide benefits for patients with this type of cancer, although the specifics of its effectiveness and potential as a standard of care are still being explored.